{"id":"NCT02634346","sponsor":"Alkermes, Inc.","briefTitle":"A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)","officialTitle":"A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Subjects With Acute Exacerbation of Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12","primaryCompletion":"2017-05-25","completion":"2017-06-07","firstPosted":"2015-12-18","resultsPosted":"2018-06-27","lastUpdate":"2018-06-27"},"enrollment":403,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"ALK3831","otherNames":[]},{"type":"DRUG","name":"Olanzapine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"ALKS 3831","type":"EXPERIMENTAL"},{"label":"Olanzapine","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the efficacy of ALKS 3831 in adult subjects with acute exacerbation of schizophrenia.","primaryOutcome":{"measure":"Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4","timeFrame":"4 weeks","effectByArm":[{"arm":"ALKS 3831","deltaMin":-23.9,"sd":1.28},{"arm":"Olanzapine","deltaMin":-22.8,"sd":1.29},{"arm":"Placebo","deltaMin":-17.5,"sd":1.32}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"0.004"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":31,"countries":["United States","Bulgaria","Serbia","Ukraine"]},"refs":{"pmids":["32141723"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":134},"commonTop":["Weight increased","Somnolence","Anxiety","Headache","Dry mouth"]}}